J2327 HCPCS Level II code: Injection, risankizumab-rzaa, intravenous, 1 mg
J2327 is the HCPCS code for “Injection, risankizumab-rzaa, intravenous, 1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J2327Injection, risankizumab-rzaa, intravenous, 1 mg
Short description: Inj risankizumab-rzaa 1 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J2327 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 2023
Where J2327 sits
- 1J codesDrugs administered other than orally
- 2Active code J2327Injection, risankizumab-rzaa, intravenous, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J2327 mean?
J2327 is the HCPCS code for “Injection, risankizumab-rzaa, intravenous, 1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J2327?
CMS lists J2327’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J2327
All J codesJ2313Injection, naloxone hydrochloride (zimhi), 0.01 mgJ2315Injection, naltrexone, depot form, 1 mgJ2320Injection, nandrolone decanoate, up to 50 mgJ2323Injection, natalizumab, 1 mgJ2325Injection, nesiritide, 0.1 mgJ2326Injection, nusinersen, 0.1 mgJ2329Injection, ublituximab-xiiy, 1mgJ2350Injection, ocrelizumab, 1 mgJ2351Injection, ocrelizumab, 1 mg and hyaluronidase-ocsqJ2353Injection, octreotide, depot form for intramuscular injection, 1 mgJ2354Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcgJ2355Injection, oprelvekin, 5 mg